Skip to content

Valneva

  • Über uns
    Über uns Advancing vaccines for better lives Mehr lesen
    • Unsere Strategie
    • Unsere Verantwortung
    • Unser Team
  • Produkte
    Produkte Fokus auf Impfstoffe gegen Infektionskrankheiten mit hohem ungedecktem Bedarf Mehr lesen
    • Japanische Enzephalitis-Impfstoff
    • Cholera-Impfstoff
    • Marketing und Vertrieb
    • Produktion und Dienstleistungen
  • R&D
    R&D Innovation in der Forschung und Entwicklung von Impfstoffen. Mehr lesen
    • Pipeline
    • Lyme Borreliose – VLA15
    • Chikungunya – VLA1553
    • COVID-19 – VLA2001
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access-Richtlinie
    • Wissenschaftliche Publikationen
  • Investoren
    Investoren Mehr lesen
    • Events und Präsentationen
      • Kalender
      • Präsentationen des Unternehmens
    • Financial & Filings
      • Finanzberichte
      • SEC Filings
    • Pressemeldungen
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Vorgeschriebene Informationen
    • Aktieninformation
      • Aktienkurs
      • Analysten
      • Aktionärsstruktur
      • Delisting von der Wiener Börse
    • Hauptversammlungen
      • 2022 Kombinierte Hauptversammlung
      • June 23, 2022 Special Meeting
      • Archiv Hauptversammlungen
    • Videos und Webcasts
    • Häufig gestellte Fragen
    • Kontakt
  • Medien
    Medien Pressemeldungen, Aktuelles und Ressourcen für Medien Mehr lesen
    • Pressemeldungen
    • In den Nachrichten
    • Ressourcen für Medien
    • Medienkontakte
  • Karriere
Kontakt
  • EN
  • FR
  • | DE
Search

Pressemeldungen

December 23, 2021

Valneva and Scottish Enterprise in Advanced Discussions for Major Grant to Complete Livingston Site

December 21, 2021

Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate

16. Dezember 2021

Valneva gibt positive homologe Booster-Daten für den inaktivierten, adjuvantierten COVID-19-Impfstoffkandidaten VLA2001 bekannt

December 8, 2021

Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001

December 3, 2021

Valneva Comments on COV-Boost Clinical Trial Data

December 2, 2021

Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001

November 29, 2021

Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001

November 23, 2021

Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001

November 18, 2021

Valneva Reports Nine-Month 2021 Revenue and Cash

November 15, 2021

Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting

  • 1
  • 2
  • 3
  • …
  • 8

Valneva

  • Über uns
  • Produkte
  • R&D
  • Investoren
  • Medien
  • Karriere
Weitere Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Kontakt
© 2022 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policygegen Japanische Enzephalitis (JE) nicht auszuüben.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policygegen Japanische Enzephalitis (JE) nicht auszuüben.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT